Aims: Hypiran is a commercial hydro-alcoholic extract of Hypericum perforatum. Its anti-inflammatory and immune modulatory benefits have been reported in several documents. This study was conducted to investigate the beneficial potential of Hypiran in the treatment of ameliorating experimental autoimmune encephalomyelitis (EAE).Materials & Methods: In this experimental study, EAE was induced by guinea pig spinal cord homogenate and complete Freund’s adjuvant in 30 male Wistar rats (6-8 weeks old, weighing 100± 20 g). Hypiran administration (110 mg/kg-P.O.-daily) was initiated at day 12 post-immunization, when the rats developed a disability score. The brains and blood samples were collected on the day 36 and used for MDA, FRAP, NO and MPO experiments.Findings: Hypiran-therapy led to a better situation in EAE rats. The lipid peroxidation level (MDA assay) was significantly increased in brain tissues of the EAE rat compared to that of the normal control one (P<0.001). Treatment with hypiran could significantly reduce the MDA levels in brain tissues of the EAE rats compared to that of the EAE rats without treatment. Moreover, Serum analysis showed that hypiran could significantly decline the nitric oxide levels as well as myeloperoxidase activity of the EAE rats compared to that of the EAE rats without treatment. Moreover, docking server analysis indicated that the hypiran could inhibit the MAO enzyme.Conclusion: It seems that hypiran may be as a promising strategy to be treatment of Multiple Sclerosis patients.